IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion
Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of
IMM2902 in the treatment of HER2-expressing advanced solid tumors